Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

11 May 2010

Abstract excerpt

BACKGROUND: Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the effect of imatinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to MicroRNA in disease regulation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 20460641
DOI: 10.3324/haematol.2009.020636

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemiaPMID 20460641Read ↗

Expression patterns of microRNAs associated with CML phases and their disease related targetsSemantic proximity Read ↗

Expression pattern of key micro<scp>RNA</scp>s in patients with newly diagnosed chronic myeloid leukemia in chronic phaseSemantic proximity Read ↗

miRNAs in chronic myeloid leukemia: small molecules, essential functionSemantic proximity Read ↗

Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot studySemantic proximity Read ↗

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistanceSemantic proximity Read ↗

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutationsSemantic proximity Read ↗

MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic ProgenitorsSemantic proximity Read ↗

microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemiaSemantic proximity Read ↗

Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progressionSemantic proximity Read ↗

Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia CellsSemantic proximity Read ↗

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemiaSemantic proximity Read ↗

Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.